Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Greenphire CEO Selected as Finalist in Ernst & Young Awards

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
CEO Sam Whitaker has been selected as a finalist for the Ernst & Young Entrepreneur of the Year Awards 2013 in the Greater Philadelphia region.

The awards recognize entrepreneurs that create and build market-leading businesses, taking standards of excellence to new heights and helping to transform the face of their respective industries. Sam was chosen from over 70 executives as a finalist for his achievements in building Greenphire into an industry leader.

Sam Whitaker, CEO of Greenphire, comments, "I am delighted to have been selected as a finalist by Ernst & Young and to be honored along with fellow nominees.  As Greenphire grows and expands internationally, it is gratifying to be recognized for our successes in transforming outdated processes in the clinical trials industry. It would not have been possible without the tireless work of all the team members at Greenphire."

Since founding Greenphire, Sam has leveraged his entrepreneurial vision to simplify processes within clinical studies, replacing burdensome manual methods with platform-driven tools that execute complex payment processes globally. In five years he has built Greenphire from a two-person concept-driven start-up to an established player in the industry. The company now employs approximately 50 people on two continents.

Awards will be presented at a black tie gala on June 20 at the Pennsylvania Convention Center.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Greenphire Awards $35,000 to Three Health and Wellness Nonprofits
NO MORE received a donation of $20,000 to further its mission to end domestic violence and sexual assault.
Wednesday, June 25, 2014
Greenphire Appoints Senior Director of Business Development in Europe
Alex Livingstone brings more than 12 years of eClinical software, pharmaceutical and biotechnology industry experience to the company.
Thursday, October 10, 2013
Greenphire Named One of the Fastest-Growing U.S Companies
The company has been ranked in the 2013 Inc. Magazine 500 list of the fastest-growing private companies in the U.S.
Wednesday, August 21, 2013
Greenphire and Ernst & Young Announce Strategic Partnership
Partnership will combine eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young.
Wednesday, July 10, 2013
Greenphire and Oracle to Work Together
New partnership to automate clinical trial planning, budgeting and payments.
Tuesday, June 25, 2013
Greenphire and IMS Health Announce Strategic Integration
Launch of strategic integration of eClinicalGPS and GrantPlan.
Friday, June 21, 2013
Greenphire's John Samar Named CFO of the Year Finalist
The Philadelphia Business Journal awards honour professionals who have displayed outstanding performance in their roles as corporate financial leaders.
Wednesday, May 29, 2013
Greenphire Announces New London Office
Plans to facilitate expansion in Europe.
Tuesday, May 07, 2013
Greenphire Appoints UK-based Global Product Manager
Appointment of Rory O’Hare to facilitate European growth.
Thursday, February 21, 2013
Greenphire Supports Proposed EU Legislation to Reduce Clinical Trial Administration
The proposed legislation expected to be enacted by 2016.
Friday, July 27, 2012
Greenphire Appoints Chief Commercial Officer
Appointment of John M Blakeley to the role of Chief Commercial Officer.
Thursday, July 12, 2012
Greenphire and Merge Healthcare Form Exclusive Partnership
Partnership to integrate clinical payment and EDC platforms.
Wednesday, May 09, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos